Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

- Lorscheider, J., Kuhle, J., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Trojano, M., Ramo-Tello, C., Lechner-Scott, J., Pucci, E., Solaro, C., Slee, M., Izquierdo, G., Van Pesch, V., Sanchez Menoyo, J. L., van der Walt, A., Butzkueven, H., Kappos, L., Kalincik, T., Lugaresi, A., Havrdova, E., Horakova, D., Hupperts, R., Duquette, P., Girard, M., Prat, A.

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

- Spelman, T., Mekhael, L., Grammond, P., Barnett, M., Lechner-Scott, J., Alroughani, R., Trojano, M., Lugaresi, A., Granella, F., Pucci, E., Vucic, S., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand'Maison, F.